AKTS - Aktis Oncology, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.00
DETAILS
HIGH:
$35.00
LOW:
$31.00
MEDIAN:
$33.00
CONSENSUS:
$33.00
UPSIDE:
50.48%
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | 6.5 | 1.5 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 6.5 | 1.5 | 0 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 67.5 | 41.0 | 25.9 | 14.3 |
| SG&A Expenses | 12.6 | 11.3 | 7.7 | 5.1 |
| Other Expenses | 1.1 | 1.3 | 1.2 | 0.4 |
| Operating Expenses | 81.2 | 53.5 | 34.8 | 19.8 |
| Operating Income | ||||
| Operating Income | (74.7) | (52.0) | (34.8) | (19.8) |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 11.0 | 8.1 | 5.4 | 1.6 |
| Profitability | ||||
| EBITDA | (61.4) | (50.5) | (33.6) | (19.3) |
| EBIT | (63.7) | (52.0) | (34.8) | (19.8) |
| Income Before Tax | (63.7) | (44.0) | (28.6) | (17.9) |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (63.7) | (44.0) | (28.6) | (17.9) |
| Per Share Data | ||||
| EPS (Basic) | -1.19 | -1.26 | -0.82 | -0.51 |
| EPS (Diluted) | -1.19 | -1.26 | -0.82 | -0.51 |
| Shares Outstanding | 52.5 | 34.9 | 34.9 | 34.9 |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Current Assets | ||||
| Cash & Cash Equivalents | 37.8 | 37.2 | 29.5 | 128.6 |
| Short-Term Investments | 189.0 | 260.0 | 68.3 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.5 | 3.7 | 2.3 | 3.9 |
| Total Current Assets | 230.3 | 300.9 | 100.2 | 132.5 |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 27.2 | 20.9 | 20.9 | 4.9 |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 7.3 | 4.5 | 1.2 | 1.0 |
| Total Non-Current Assets | 34.6 | 25.3 | 22.2 | 5.8 |
| Total Assets | 264.9 | 326.2 | 122.4 | 138.3 |
| Current Liabilities | ||||
| Account Payables | 1.7 | 1.9 | 1.0 | 0.5 |
| Short-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Revenue | 18.7 | 9.3 | 0 | 0 |
| Other Current Liabilities | 4.6 | 3.1 | 2.0 | 1.2 |
| Total Current Liabilities | 31.2 | 18.8 | 6.2 | 5.3 |
| Non-Current Liabilities | ||||
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 333.4 | 333.4 | 150.6 | 151.4 |
| Total Non-Current Liabilities | 379.8 | 395.2 | 162.4 | 152.3 |
| Total Liabilities | 411.0 | 414.0 | 168.7 | 157.6 |
| Stockholders' Equity | ||||
| Common Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | (156.6) | (92.8) | (48.9) | (20.2) |
| Accumulated Other Comprehensive Income | 0.0 | 0.1 | 0.1 | 0 |
| Total Stockholders' Equity | (146.1) | (87.8) | (46.3) | (19.2) |
| Total Liabilities & Equity | 264.9 | 326.2 | 122.4 | 138.3 |
| Debt Metrics | ||||
| Total Debt | 11.5 | 12.0 | 13.4 | 1.8 |
| Net Debt | (26.2) | (25.1) | (16.1) | (126.8) |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | (63.7) | (44.0) | (28.6) | (17.9) |
| Depreciation & Amortization | 2.3 | 1.6 | 1.1 | 0.4 |
| Stock-Based Compensation | 5.1 | 2.3 | 1.5 | 0.7 |
| Change in Working Capital | (3.2) | 59.0 | (0.0) | (1.1) |
| Other Non-Cash Items | (4.6) | (4.1) | (3.9) | (0.2) |
| Operating Cash Flow | (64.1) | 14.8 | (30.0) | (18.1) |
| Investing Activities | ||||
| Capital Expenditure | (9.6) | (2.9) | (3.8) | (2.3) |
| Acquisitions | 0 | 0 | 0 | 0 |
| Purchases of Investments | (193.9) | (288.4) | (145.8) | 0 |
| Sales/Maturities of Investments | 269.4 | 100.9 | 80.7 | 0 |
| Other Investing Activities | 0 | 0 | 0.1 | 0 |
| Investing Cash Flow | 66.0 | (190.4) | (68.8) | (2.3) |
| Financing Activities | ||||
| Net Debt Issuance | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.5) | (1.7) | 0 | (0.2) |
| Financing Cash Flow | (1.2) | 183.3 | 0 | 120.0 |
| Cash Position | ||||
| Net Change in Cash | 0.6 | 7.6 | (98.8) | 99.6 |
| Cash at Beginning | 38.3 | 30.7 | 129.5 | 29.9 |
| Cash at End | 38.9 | 38.3 | 30.7 | 129.5 |
| Free Cash Flow | (73.7) | 11.9 | (33.8) | (20.4) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 6.5 | 1.5 | 0 | 0 |
| Gross Profit | 6.5 | 1.5 | 0 | 0 |
| Operating Income | (74.7) | (52.0) | (34.8) | (19.8) |
| Net Income | (63.7) | (44.0) | (28.6) | (17.9) |
| EPS (Diluted) | -1.19 | -1.26 | -0.82 | -0.51 |
| Balance Sheet | ||||
| Cash & Equivalents | 37.8 | 37.2 | 29.5 | 128.6 |
| Total Assets | 264.9 | 326.2 | 122.4 | 138.3 |
| Total Debt | 11.5 | 12.0 | 13.4 | 1.8 |
| Stockholders' Equity | (146.1) | (87.8) | (46.3) | (19.2) |
| Cash Flow | ||||
| Operating Cash Flow | (64.1) | 14.8 | (30.0) | (18.1) |
| Capital Expenditure | (9.6) | (2.9) | (3.8) | (2.3) |
| Free Cash Flow | (73.7) | 11.9 | (33.8) | (20.4) |